Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer

Last updated: September 25, 2019
Sponsor: University Hospital, Tours
Overall Status: Completed

Phase

N/A

Condition

Gastric Ulcers

Stomach Cancer

Gastric Cancer

Treatment

N/A

Clinical Study ID

NCT02573974
PHAO14-TL/METERMUCADIG
150963B-12
2015-R25
2015-A00683-46
  • Ages 18-80
  • All Genders

Study Summary

Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. Despite undeniable progress in knowledge, many pathophysiological mechanisms remain few or not explored, which could explain that there is still no satisfactory therapeutic solution to halt the gradual deterioration of the nutritional status of patients. In this sense, apart from preclinical data obtained in animal models, there is currently no clinical study on the functioning of skeletal muscle energy metabolism in undernourished patients suffering of cancer.

Eligibility Criteria

Inclusion

Case group selection criteria: Inclusion Criteria:

  • 18 years ≤ Age ≤ 80 years

  • Colorectal pancreatic cancer

  • Undernutrition related to cancer (weight loss > 5% weight in one month or 10% in 6months)

  • Indication to systemic chemotherapy

  • Indication to the development of an implantable port

  • Life expectancy ≥ 3 months

  • WHO General Status ≤ 2

  • Patients affiliated to social security scheme

  • Informed consent signed by the patient

Exclusion

Exclusion Criteria:

  • Pregnant or breastfeeding women

  • Unbalanced Diabetes

  • Systemic corticosteroid treatment

  • Any severe uncontrolled medical condition

  • Alopecia Control group selection criteria: Inclusion Criteria:

  • 18 years ≤ Age ≤ 80 years

  • Colorectal pancreatic cancer

  • Indication adjuvant chemotherapy

  • Indication to the development of an implantable port

  • Life expectancy ≥ 3 months

  • WHO General Status ≤ 2

  • Patients affiliated to social security scheme

  • Informed consent signed by the patient Exclusion Criteria:

  • Pregnant or breastfeeding women

  • Undernutrition related cancer (weight loss > 5% weight in one month or 10% in 6months)

  • Unbalanced Diabetes

  • Systemic corticosteroid treatment

  • Any severe uncontrolled medical condition

  • Alopecia

Study Design

Total Participants: 51
Study Start date:
January 19, 2016
Estimated Completion Date:
December 04, 2018

Connect with a study center

  • Service d'Hépato-gastroentérologie et de Cancérologie Digestive, CHRU de TOURS

    Tours, 37044
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.